Enabling
Cell Therapy

Our ApoGraft™ technology turns production of cell-based therapies into a simple, safe and inexpensive process

Learn more about Cellect

Understanding Cellect in 2 minutes

Key Milestones

JUL 2016

Cellect raises $8.4M

JAN 2017

US Patent Notice of Allowance

FEB 2017

First Cancer Patient Treated In Phase I/II Trial Positive Clinical Results

MAR 2017

Successful First Cancer Patient Stem Cell Transplant

JUN 2017

Cellect Receives Russian Patent

SEP 2017

FDA Grants Cellect Orphan Drug Status for ApoGraft™

SEP 2017

Cellect raises $4.3M

JAN 2018

Positive Clinical Trial Results100% Acceptance and Zero Related Adverse Events

JAN 2018

Cellect raises $4.0M

JAN 2018

Opening 2nd Clinical Trial Site DSMB Approves Dose Escalation

APR 2018
Successfully completes POC testing for scalable production of ApoTainer™

JUL 2018
Signs Collaboration Agreement with Dresden University

AUG 2018
Cellect Granted Key European Patent for Stem Cells Selection Technology

AUG  2018
Korean Patent
Notice of Allowance

JUL 2019
Washington University (US) clinical collaborative agreement

OCT 2019
Cellect receives an FDA IND approval

JAN 2020
Cellect raises $3.0M

APR 2020
Canadian patent granted. Overall 9 company owned patent families: 45 granted, 17 pending, 2 PCT applications

MAY 2020
Positive results of ongoing clinical trial. Robust engraftment and no safety and tolerability issues.

MAY 2020
Cellect raises $1.5M

The People Behind our Company

Our Advisory Board

ADITYA MOHANTY
Ex-CEO Biotime, President Shire Regenerative Medicine
Prof. SUSAN ALPERT
Ex FDA
Prof. YEHUDA SHOENFELD
Sheba Medical Center
Prof. COREY CUTLER
Harvard Medical School
Prof. ROBERT S. NEGRIN
Stanford University
Prof. DOV ZIPORI
Weizmann Institute of Science

Our Board of Directors

ABRAHAM NAHMIAS
Chairman of the Board
DAVID BRAUN
Merck
JONATHAN BURGIN
SIVAN RAHAMIM

Our Management

Dr. SHAI YARKONI
Co-Founder & CEO
EYAL LEIBOVITZ
CFO
AMOS OFER
COO
SMADAR HAR TUV
QA & RA
GALINA RODIONOV
R&D Senior Director
CHELI GONNEN
Clinical Operations

Cellect Principles Simplified

Regenerative medicine

It is all about replacing damaged tissues and organs instead of "fixing" them with drugs and radiations

Regrowth of organs and tissues is no longer a science fiction

Stem cells are the building blocks....

... but they are extremely rare and difficult to cultivate

The process takes weeks in specialty labs, remains highly ineffective and its costs keep stem cell treatments a privilege of the elitist-few who can afford it

Cellect changes all that.

We enable safe and effective stem cells selection within hours and at a fraction of the cost - for all people

We make stem cells based regenerative medicine possible on mass scale

ENABLING STEM CELLS